Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows

Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows
The combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) is safe and shows clinically meaningful activity, leading to lasting responses in men with metastatic castration-resistant prostate cancer (mCRPC), a Phase 1b trial shows. The trial's findings were presented in a poster, "Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study," at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2020), held recently in San Francisco. The global, open-label COSMIC-021 Phase 1b trial (NCT03170960) is evaluating the safety, tolerability, and preliminary efficacy of Exelixis’ Cabometyx in combination with Genentech’s Tecentriq in people with different types of solid cancers. The trial also is assessing the combination's pharmacokinetic properties — how a drug is absorbed, distributed, and metabolized in the body, then eliminated. In total, the study aims to enroll up to 1,732 participants with 12 types of solid tumors, including CRPC,
Subscribe or to access all post and page content.